Non-invasive brain stimulation in chronic orofacial pain: a systematic review

Alberto Herrero Babiloni1
Samuel Guay1
Donald R Nixdorf2,3
Louis de Beaumont1
Gilles Lavigne1

1Research Center, Hôpital du Sacré-Cœur de Montréal, CIUSSS du Nord-de-l’Île-de-Montréal, Université De Montréal, Montreal, QC, Canada; 2Division of TMD & Orofacial Pain, School of Dentistry, University of Minnesota, Minneapolis, MN, USA; 3Department of Neurology, Medical School, University of Minnesota, Minneapolis, MN, USA

Background: Transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) are non-invasive brain stimulation techniques that are being explored as therapeutic alternatives for the management of various chronic pain conditions.

Objective: The primary objective of this systematic review is to assess the efficacy of TMS and tDCS in reducing clinical pain intensity in chronic orofacial pain (OFP) disorders. The secondary objectives are to describe adverse effects, duration of relief, and TMS/tDCS methodologies used in chronic OFP disorders.

Methods: A search was performed in MEDLINE, Embase, Web of Science, Scopus, and Google Scholar. Inclusion criteria were 1) population: adults diagnosed with chronic OFP including neuropathic and non-neuropathic disorders; 2) intervention: active TMS or tDCS stimulation regardless of the used protocol; 3) comparison: sham TMS or tDCS stimulation; and 4) outcome: primary outcome was patient reported pain intensity. Secondary outcomes were duration of pain relief, adverse effects, and methodological parameters. Risk of bias and quality of study reporting were also assessed.

Results: A total of 556 individual citations were identified by the search strategy, with 14 articles meeting selection criteria (TMS=11; tDCS=3). Data were obtained for a total of 228 patients. Included OFP disorders were trigeminal neuralgia, trigeminal neuropathy, burning mouth syndrome, atypical facial pain, and temporomandibular disorders. Significant pain reductions were obtained in both techniques. More number of sessions yielded to more durable effects. Overall, high risk of bias and poor study quality were found.

Conclusion: TMS and tDCS appear to be safe and promising alternatives to reduce pain intensity in different chronic OFP disorders. Additional research effort is needed to reduce bias, improve quality, and characterize optimal brain stimulation parameters to promote their efficacy.

Keywords: transcranial magnetic stimulation, transcranial direct current stimulation, cortex, treatment, facial pain

Introduction

Chronic orofacial pain (OFP) is an umbrella term to describe different non-remittent painful disorders located in the face and/or inside the mouth. OFP has been estimated to affect approximately 39 million adults, or 22% of the population, in the USA. When OFP becomes chronic (≥6 months), it is frequently associated with psychological distress, disability, and poor quality of life, making its treatment difficult and often refractory to conventional therapies and resulting in a high economic burden.

Transcranial magnetic stimulation (TMS) is a non-invasive brain stimulation technique that uses changes in magnetic fields to increase or decrease neuronal activity. Its
application is delivered through a magnetic coil placed over the head that transforms electrical current into a magnetic field, which can be focalized to different areas of the brain. In broad terms, different effects can be obtained depending on what area is stimulated and what frequency is used. For example, low frequencies (≤1 Hz) can induce neuronal inhibitory function, whereas high frequencies (≥25 Hz) are typically associated with increased cortical excitability. Repeated stimulation to the left prefrontal cortex is frequently associated with antidepressant and mood stabilizer effects, while repeated stimulation of the primary motor cortex (M1), which is usually applied to the contralateral side of the painful area, can produce analgesic effects. It is thought that the analgesic effects of M1 stimulation may be mediated by the activation of horizontal fibers in the superficial layers of the precentral gyrus. It has been demonstrated that when TMS current is propagated throughout the brain from anterior to posterior, TMS can generate late I-waves, and this orientation has been associated with pain relief. Another TMS modality is theta burst stimulation (TBS), which delivers a significantly higher number of stimulation bursts within a shorter period of time (<2 min) when compared to conventional repetitive TMS (rTMS) protocols. This stimulation may be continuous (cTBS), leading toward a cortical inhibitory effect, or intermittent (iTBS), which has excitatory effects. Human response to TBS is influenced by the intra- and interindividual variability of cortical excitability. It is likely that the same pattern of stimulation can trigger different effects in different subjects, probably also depending on the physiological resting state of cortical neurons at the time of stimulation. The neurobiological mechanisms of TBS may involve long-term potentiation (LTP) and depression (LTD)-like processes, as well as inhibitory mechanisms modulated by GABAergic activity. Therefore, although their mechanisms are not fully understood, different rTMS techniques are emerging as alternative treatment options to manage chronic pain disorders, including neuropathic pain, fibromyalgia, and headache disorders, as well as evidence-based guidelines have been developed to investigate its therapeutic use.

Another non-invasive technique that can modulate neuronal function is transcranial direct current stimulation (tDCS). Its functioning is based on weak electrical currents that are applied over the scalp through electrodes for a specific amount of time. Usually, one electrode is placed over the target region, while a second electrode is placed over a reference area in order to create a closed circuit. Depending on the electrodes, the stimulation can be anodal (producing membrane depolarization, lowering firing thresholds, and consequently increasing neuronal firing) or cathodal (producing membrane hyperpolarization and consequently decreasing neuronal firing). Similar to TMS, tDCS can be used for different purposes, including the management of chronic pain conditions. Moreover, evidence-based guidelines have also been established for the therapeutic use of tDCS.

The effectiveness of these two techniques for the management of chronic pain has been assessed comprehensively in neuropathic pain disorders or fibromyalgia. However, the trigeminal nerve has a number of distinct structures and associated specializations that are not present in spinal nerve distributions. These include innervation of all the special senses, greater percentage of C-fibers than A-delta fibers in some tissue (ie, pulp of teeth), elevated coalescence between sensory and motor roots, and greater spatial degree of peripheral integration, among others. Therefore, the anatomical and functional differences of the trigeminal nerve make OFP disorders less comparable with other disorders presenting in spinal territories.

Although other reviews have assessed the efficacy of non-invasive brain stimulation in different headache disorders, no comprehensive evaluation has been performed in other chronic OFP disorders. Thus, the aim of this systematic review is to assess the efficacy of active TMS and tDCS to reduce pain intensity in different chronic OFP disorders when compared to sham (inactive) stimulation. We also aimed to report relief duration, associated adverse effects, and describe different methodologies used.

Methods

The review protocol was registered in the International Prospective Register for Systematic Reviews (PROSPERO, protocol CRD42018085762). Recommendations of the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement were followed. Eligibility criteria were as follows:

1) Population: adult patients (>18 years old) diagnosed with temporomandibular disorders (TMDs), burning mouth syndrome (BMS), persistent dentoalveolar pain (PDAP), atypical facial pain, trigeminal neuralgia (TN), postherpetic neuralgia, trigeminal neuropathic pain, or trigeminal neuropathy.
2) Intervention: active TMS or tDCS stimulation using any protocol.
3) Comparison: sham TMS or tDCS stimulation.
4) Outcome: primary outcome was clinical pain intensity. Secondary outcomes were duration of pain relief, adverse effects, and methodological parameters.
Controlled trials were included. Case reports, clinical observations, and animal studies were excluded. There was no restriction for language of publication or publication date. Studies that did not present individualized results for the face were not included.

**Search strategy**

Literature search was performed in MEDLINE (Ovid interface) and adapted to Embase, Web of Science, EMB, Scopus, Cochrane Central Register of Controlled Trials, and Google Scholar. Ongoing trials and systematic reviews were searched in Clinical Trial Registry (clinicaltrials.gov) and PROSPERO, respectively. The search process was guided by a trained librarian (NC) from Université de Montréal. A detailed search for MEDLINE is described in Box 1. Additionally, hand search was performed using the references of included studies and reviews about non-invasive brain stimulation for identification of other potentially eligible studies. Results of the search were imported into EndNote X7 (Clarivate Analytics, Philadelphia, PA, USA) for removal of duplicates and reference management. The individual references were exported to a spreadsheet with the following information: authors, year of publication, article title, journal, volume, issue, and abstract.

**Screening of references and eligibility assessment**

Based on the titles and the abstracts, two of the authors (AHB and SG) screened the references independently. Both of them had previous training in the application of the eligibility criteria using 20 randomly selected references. A calibration procedure was then performed with 50 randomly selected references independently reviewed by both raters, resulting in perfect agreement (Cohen’s kappa coefficient = 1.00).26 Then, the rest of the references were screened by the two raters who were blinded to each other. The agreement for the screening process between them was very good (Cohen’s kappa coefficient = 0.87). Consensus between the two reviewers was attempted when disagreement occurred, while a third rater (GL) arbitrated when consensus could not be reached. Full-length articles of potential references were obtained in order to assess eligibility, which was also done blindly and compared by the same raters using the same process as previously described for references.

**Data extraction and study variables**

The articles that met inclusion criteria were obtained in electronic format. Data extraction was performed individually by one author (AHB) and then revised by a second author (SG). If a disagreement occurred, reconciliation between these two authors was performed. Extracted data were number of patients who received active/sham stimulation, age, number of females, type of TMS/tDCS, brain target area, frequency, intensity of stimulation, number of sessions, number of pulses per session (TMS), duration of stimulation (tDCS), adverse effects, and qualitative main results.

**Risk of bias assessment**

Individual risk of bias was assessed independently by two authors (AHB and SG) using the Cochrane Risk of Bias

---

**Box 1 Ovid MEDLINE search strategy**

```
TMS (transcranial magnetic stimulation):
Transcranial Magnetic Stimulation/(transcranial magnetic stimulation* or TMS or rTMS or Theta burst).ab,ti.

OR
tDCS (transcranial direct current stimulation):
Transcranial Direct Current Stimulation/(transcranial adj3 (direct current or random noise or alternating current or electrical) adj3 stimulation).ab,ti.

AND
Orofacial pain:
exp Facial Pain/(face or facial or orofacial or craniofacial or myofacial or tooth) adj3 pain) or (toothache or odontalgia or PDAP or phantom tooth pain or postendodontic pain).ab,t.i; exp Craniomandibular Disorders/or Temporomandibular Joint/(craniomandibular disorders or (temporomandibular or TMJ) or tempo-ro-mandibular) adj3 (joint or disease* or disorder*)) or TMD or TMJD or CMD).ab,t.i; Myofascial Pain Syndromes/or (myofascial pain syndrome* or myofascial trigger point pain).ab,t.i; Neuralgia, Postherpetic/or (PHN or postherpetic neuralgia).ab,t.i; Burning Mouth Syndrome/or Glossalgia/(burning mouth or glossalgia* or stomatodynia* or stomatopyrosis* or glossodynia* or glossopyrosis* or (oral adj3 dysenthesia*)).ab,t.i; exp Facial Neuralgia/or neuralgia/(facial neuralgia* or sphenopalatine neuralgia* neuropathic pain* or (trigeminal adj3 (nerve disease* or neuropathy* or nerve disorder* or neuralgia*) or raeder paratrigeminal syndrome or cranial nerve V disease* or fifth cranial nerve disease* or (trifacial or epileptiform) adj neuralgia*) or Fothergill disease or tic douloureux).ab,t.i; Trigeminal Nerve Injuries/or (trigeminal nerve injuries or PTTN or trigeminal painful neuropathy).ab,t.i.
```
Tool for randomized controlled trials.27 If any disagreement occurred, consensus was attempted, and if the disagreement persisted a third author (GL) arbitrated. The following criteria were considered: sequence generation (selection bias), allocation sequence concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective outcome reporting (reporting bias), and other potential sources of bias. Risk of bias was then classified as low, unclear, or high. Quality of evidence (poor, fair, or good) was obtained by converting these data using the proposed thresholds for Agency for Healthcare Research and Quality (AHRQ) standards.

To reduce publication bias, besides searching reference lists of included articles and systematic reviews about non-invasive brain stimulation, we also searched references in abstracts and posters and contacted corresponding authors if data were missing or were unclear. If they did not reply, the reference was not included in the final selection. As studies were too heterogeneous, a meta-analysis was not performed. Therefore, data are presented in a narrative way.

Results
Overview of included studies
Our search generated a total of 556 references from the previously mentioned databases. From those, 29 were selected for full-length text retrieval and 14 met the selection criteria.28–41 Hand search of the references from the eligible studies revealed two more studies that were also included in the full-length text retrieval phase but that did not meet the inclusion criteria. Figure 1 depicts a more detailed description of this process using a PRISMA flow diagram. Importantly, ten references were not included as individualized OFP data could not be extracted from the accessible results, which included chronic pain disorders that can be present in the face. Thus, 11 TMS28–38 and 3 tDCS39–41 studies

Figure 1 PRISMA flow diagram.
were included in this systematic review providing data on a total of 228 patients.

Table 1 summarizes the characteristics, including a description of inclusion and exclusion criteria for each of the 14 studies. Most of the studies were conducted in France \((k=4)\) and the USA \((k=3)\). Six of them had a parallel design, while eight were conducted in a crossover design. It appears that rTMS was used more in neuropathic pain disorders (trigeminal neuropathy and TN), conditions with neuropathic features (BMS, PDAP, and related disorders) and not clearly defined, atypical facial pain disorders. Only four rTMS studies were specifically designed for OFP disorders.31,34,37,38 The remaining two studies included chronic pain disorders (ie, neuropathic pain) affecting other body areas in addition to the face. In contrast, all tDCS studies were exclusively designed for OFP disorders, exploring the role of tDCS in treating TN or TMD pain.

Methodological parameters and main results
As the underlying action mechanisms of rTMS are thought to differ from those of tDCS, the results for each technique are reported separately (Tables 2 and 3, respectively). In the 11 rTMS studies, 162 patients were recruited. All of the included studies used high frequency rTMS but one, which used an intermittent theta burst stimulation (iTBS) protocol.34 Three of the rTMS studies stimulated different brain areas in a within-subject design and compared the efficacy of the different stimulation locations. Globally, all the studies but one reported significant reductions in pain intensity when compared to sham in at least one of the stimulated areas (Table 3). The targeted brain areas were left prefrontal cortex (LPFC) \((k=2)\), M1 areas corresponding to the hand \((k=4)\) or face \((k=7)\) and right secondary somatosensory and motor cortex (M2/S2) \((k=1)\). Stimulation with rTMS in LPFC, M1 corresponding to the hand, and M2/S2 was associated with significant pain improvement. However, the results after stimulation with rTMS and iTBS in M1 representation of the face were less consistent, with three \((3/7)\) rTMS studies showing no improvement and the iTBS study showing modest and transient relief. Stimulation frequencies for rTMS studies were 5 Hz \((k=1)\), 10 Hz \((k=6)\), and 20 Hz \((k=3)\), while intensities of stimulation ranged between 80% and 110% of the resting motor thresholds. The iTBS study used bursts of 50 Hz at 90% of the resting motor threshold for 600 stimulations for one session only.34 It also appears that doing multiple sessions of stimulation (5 or 10 sessions) induced more durable analgesic effects, lasting up to 2 weeks in studies using five sessions31,33 and 60 days in a study that used 10 sessions.38 Although it was not reported in four studies, the presence of side effects was minimal across the remaining studies, mainly consisting in mild transient headaches \((k=3)\) (Table 2).

For tDCS, 66 patients participated in the three included studies (Table 4). All the studies used anodal tDCS over M1 corresponding to the face. Used intensities were 1 mA \((k=1)\) and 2 mA \((k=2)\) for a single 20-min session. Two studies reported significant pain improvement when compared to sham,39,40 while a third study, which provided physical therapy in addition to active and sham tDCS, reported pain improvement effects similar to the sham condition.41 From those reporting differences, the effects of the intervention lasted up to 4 weeks in one study and 6 weeks in the other one. Minor side effects were present in two of the studies and consisted mainly of mild transient headaches, itching/tingling, and sleepiness (Table 3).

Risk of bias and quality of studies
Overall, the quality of the study reporting was poor \((12/14)\) with only two studies being assessed as having fair quality.32,41 Therefore, no study presented good reporting quality according to our assessment. High and unclear selection bias, detection bias, and other bias were present in the majority of the studies (Table 4). Although two studies reported no randomization, seven studies reported having performed a randomization strategy but without further specification about the process. Allocation concealment was only reported in two studies.32,41 Although blinding of participants was reported in all the studies but one, blinding of outcome assessment was only reported in six studies. Other considered bias included the intake of anticonvulsant medication, which was unclear or high in all the studies but one,30 and the lack of an appropriate control group.41

Discussion
The results obtained from the studies included in this systematic review indicate that TMS, and in a more limited way tDCS, are safe and effective techniques for reducing patient reported pain intensity when compared to sham stimulation in chronic OFP disorders. These pain reductions were maintained for at least 8 days and up to 60 days in 5 of the 14 studies.

TMS
The effects of TMS are influenced by stimulation parameters. These mainly include target brain area (where the magnetic
**Table 1** Study characteristics

<table>
<thead>
<tr>
<th>Study</th>
<th>Country</th>
<th>Study design</th>
<th>OFP condition</th>
<th>Inclusion criteria</th>
<th>Exclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andre-Obadia et al, 2018</td>
<td>France</td>
<td>Crossover</td>
<td>Trigeminal neuropathy</td>
<td>Pharmacoresistant neuropathic pain for 1 year or longer, stable medication last month</td>
<td>Epidemic, addiction, migraine, intracranial ferromagnetic material, or implanted stimulator (intracerebral or not, such as pacemaker)</td>
</tr>
<tr>
<td>Ayache et al, 2016</td>
<td>France</td>
<td>Crossover</td>
<td>TN after surgery, atypical facial pain after dental surgery</td>
<td>Chronic refractory unilateral neuropathic pain, stable medication</td>
<td>No contraindications to magnetic stimulation, including no history of epilepsy and/or ferromagnetic implant</td>
</tr>
<tr>
<td>Borckardt et al, 2009</td>
<td>USA</td>
<td>Crossover</td>
<td>Trigeminal neuropathy, atypical facial pain</td>
<td>Chronic neuropathic pain for 1 year or longer</td>
<td>Family history of epilepsy, seizures, implanted devices, history of tumors or brain abnormalities, implanted metal in the head, neck, or chest, and medications that lower seizure threshold</td>
</tr>
<tr>
<td>Fricova et al, 2013</td>
<td>Czech Republic</td>
<td>Parallel</td>
<td>TN after dental or neural surgery, atypical facial pain</td>
<td>18–65-year-old patients with pharmacoresistant facial pain for 6 months or longer while on stable analgesic medication</td>
<td>Severe organic brain damage, serious diseases, epilepsy, or metallic implants in the body</td>
</tr>
<tr>
<td>Hosomi et al, 2013</td>
<td>Japan</td>
<td>Crossover</td>
<td>Trigeminal neuropathic pain</td>
<td>≥20-year-old patients with neuropathic pain per IASP criteria for more than 6 months, stable medications</td>
<td>Inability to fill the questionnaires, dementia, aphasia, major psychiatric disease, suicidal wish, pregnancy, and contraindications to TMS, like implantation of a cardiac pacemaker</td>
</tr>
<tr>
<td>Khedr et al, 2005</td>
<td>Egypt</td>
<td>Parallel</td>
<td>TN</td>
<td>TN diagnosis as IASP criteria</td>
<td>Intracranial metallic devices, pacemakers or any device, extensive myocardial ischemia, and epilepsy</td>
</tr>
<tr>
<td>Kohutova et al, 2017</td>
<td>Czech Republic</td>
<td>Parallel</td>
<td>Chronic OFP</td>
<td>18–65-year-old patients with pharmacoresistant facial pain for 6 months or longer while on stable analgesic medication</td>
<td>Severe organic brain damage, serious diseases, epilepsy, or metallic implants in the body</td>
</tr>
<tr>
<td>Lefaucheur et al, 2001</td>
<td>France</td>
<td>Crossover</td>
<td>Trigeminal neuropathy after surgery</td>
<td>Chronic unilateral pharmacoresistant neuropathic pain</td>
<td>History of seizures</td>
</tr>
<tr>
<td>Lefaucheur et al, 2004</td>
<td>France</td>
<td>Crossover</td>
<td>Trigeminal nerve lesion (failure of TN surgery)</td>
<td>Chronic unilateral pharmacoresistant neurogenic pain</td>
<td>History of seizures</td>
</tr>
<tr>
<td>Lindholm et al, 2015</td>
<td>Finland</td>
<td>Crossover</td>
<td>Trigeminal neuropathic pain, atypical facial pain, and BMS</td>
<td>Chronic daily neuropathic pain as per ICHD 2013, with 4/10 pain intensity, stable medication</td>
<td>History of seizure, pacemaker implantation, major stroke, or other contra-indication for TMS</td>
</tr>
<tr>
<td>Umezaki et al, 2016</td>
<td>USA</td>
<td>Parallel</td>
<td>BMS</td>
<td>Daily deep bilateral burning sensation of oral mucosa at least 4–6 months, constant/increasing intensity during day, no worsening but possible improvement on eating/drinking, no interference with sleep and normal aspect. Stable medications</td>
<td>Evident inflammation or autoimmune disease, current primary psychiatric condition, history of substance abuse, history of seizures, brain surgery, intracranial hypertension, pace-maker or other metallic implants, medication changes within 4 weeks of starting or during the trial</td>
</tr>
<tr>
<td>Donnell et al, 2015</td>
<td>USA</td>
<td>Parallel</td>
<td>TMD (myofascial)</td>
<td>18–65-year-old patients with daily chronic myofascial TMD based on RDC/TMD, not adequately controlled by conventional therapy for a year, surgery naïve, pain 3/10 2 weeks before the study, and stable medication</td>
<td>Pain not primarily due to myofascial TMS, history of current evident neurological disorder (epilepsy, major depression, stroke, neuropathy, or neuropathic pain)</td>
</tr>
<tr>
<td>Hagenacker et al, 2014</td>
<td>Germany</td>
<td>Crossover</td>
<td>TN</td>
<td>Classic TN with/without concomitant persistent pain per ICDH3, last 6 months stable medication</td>
<td>Other pain disorders and other disorders of the nervous system</td>
</tr>
<tr>
<td>Oliveira et al, 2015</td>
<td>Brazil</td>
<td>Parallel</td>
<td>TMD (myofascial)</td>
<td>Patients with myofascial pain or myofascial with limited opening per RDC/TMD with 4/10 intensity in the last 6 months</td>
<td>Physical therapy in the last month, rheumatic or cardiovascular disease, metal implant in the brain or skull</td>
</tr>
</tbody>
</table>

**Note:** Pharmacoresistant defined as persistence of pain, despite at least two attempts at pharmacological treatment in the past, both of sufficient dose and sufficient time.

**Abbreviations:** BMS, burning mouth syndrome; ICHD, International Classification of Headache Disorders; IASP, International Association for the Study of Pain; OFP, orofacial pain; TMD, temporomandibular disorders; TMS, transcranial magnetic stimulation; TN, trigeminal neuralgia; RDC, research diagnostic criteria.
Table 2 TMS methodology and main results

<table>
<thead>
<tr>
<th>Study</th>
<th>Sample size</th>
<th>Age, years (mean ± SD)</th>
<th>Female (%)</th>
<th>Pain intensity (mean ± SD) (0–10)</th>
<th>Type</th>
<th>Target area</th>
<th>Frequency, intensity</th>
<th>Pulses/session, no. sessions</th>
<th>Adverse effects</th>
<th>Main results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andre-Obadia et al, 2018³⁰</td>
<td>12</td>
<td>50.6 ± 13.1</td>
<td>9 (75%)</td>
<td>7.05 ± 0.54</td>
<td>rTMS</td>
<td>M1 hand and b) face</td>
<td>20 Hz, 90%, MEPs</td>
<td>1600/session, 1 session</td>
<td>N/A</td>
<td>Significant pain reduction with M1 hand stimulation but not with M1 face</td>
</tr>
<tr>
<td>Ayache et al, 2016³¹</td>
<td>16</td>
<td>47.7 ± 13.1</td>
<td>2 (67%)</td>
<td>5.6 ± 0.6</td>
<td>rTMS</td>
<td>Somatotopic localization of affected orofacial M1 area</td>
<td>5 Hz, 90%, MEPs</td>
<td>500/session, 10 sessions</td>
<td>N/A</td>
<td>Significant immediate pain reduction</td>
</tr>
<tr>
<td>Borckardt et al, 2009³⁰</td>
<td>13 active</td>
<td>47.7 ± 13.1</td>
<td>2 (67%)</td>
<td>6.0 ± 1.2</td>
<td>iTBS</td>
<td>Somatotopic localization of affected orofacial M1 area</td>
<td>50 Hz, 90%, MEPs</td>
<td>600/session, 1 session</td>
<td>Mild HA</td>
<td>Significant modest pain reduction after the treatment but not 2 weeks after</td>
</tr>
<tr>
<td>Fricova et al, 2013³¹</td>
<td>10 sham</td>
<td>59.3 ± 14.9</td>
<td>6 (67%)</td>
<td>5.4 ± 1.6 active</td>
<td>rTMS</td>
<td>M1 representation</td>
<td>10 Hz, 80%, MEPs</td>
<td>1000/session, 5 sessions</td>
<td>N/A</td>
<td>Significant reduction immediately after the treatment maintained 8 days after</td>
</tr>
<tr>
<td>Hosomi et al, 2013³²</td>
<td>6 active</td>
<td>55.5 ± 12.7</td>
<td>6 (60%)</td>
<td>5.9 ± 1.8</td>
<td>rTMS</td>
<td>M1 representation</td>
<td>10 Hz, 90%, MEPs</td>
<td>3000/session, 3 sessions</td>
<td>None</td>
<td>Significant pain reduction immediately after the treatment maintained 2 weeks after</td>
</tr>
<tr>
<td>Khedr et al, 2005³³</td>
<td>14 active</td>
<td>50.6 ± 13.1</td>
<td>11 (69%)</td>
<td>11 (69%)</td>
<td>rTMS</td>
<td>M1 representation</td>
<td>10 Hz, 90%, MEPs</td>
<td>4000/session, 3 sessions</td>
<td>N/A</td>
<td>Significant pain reduction when controlling for mood, sleep and activity level</td>
</tr>
<tr>
<td>Kohoutova et al, 2017³⁴</td>
<td>10 active</td>
<td>59.3 ± 14.9</td>
<td>6 (67%)</td>
<td>6.0 ± 1.2</td>
<td>iTBS</td>
<td>M1 representation</td>
<td>10 Hz, 90%, MEPs</td>
<td>720/session, 5 sessions</td>
<td>N/A</td>
<td>Significant pain reduction in sensory thresholds at the end of treatment maintained 2 weeks after</td>
</tr>
<tr>
<td>Lefaucheur et al, 2001³⁵</td>
<td>7</td>
<td>57.2</td>
<td>6 (60%)</td>
<td>6.0 ± 1.0</td>
<td>rTMS</td>
<td>Masseter</td>
<td>10 Hz, 80%, MEPs</td>
<td>N/A, 1 session</td>
<td>None</td>
<td>Significant pain reduction immediately after the treatment maintained 8 days after</td>
</tr>
<tr>
<td>Lefaucheur et al, 2004³⁶</td>
<td>12</td>
<td>N/A</td>
<td>N/A</td>
<td>3.4 ± 0.6</td>
<td>rTMS</td>
<td>M1 representation</td>
<td>10 Hz, 90%, MEPs</td>
<td>N/A, 1 session</td>
<td>None</td>
<td>Significant pain reduction immediately after the treatment maintained 8 days after</td>
</tr>
<tr>
<td>Lindholm et al, 2015³⁷</td>
<td>16</td>
<td>63.4 ± 10.8</td>
<td>11 (92%)</td>
<td>6.8 ± 0.6</td>
<td>rTMS</td>
<td>Left prefrontal cortex</td>
<td>10 Hz, 110%, MEPs</td>
<td>3000/session, 10 sessions</td>
<td>Mild HA</td>
<td>Significant pain reduction immediately after the treatment maintained 60 days after treatment start. No reduction in psychosocial scores</td>
</tr>
<tr>
<td>Umezaki et al, 2016³⁸</td>
<td>12 active</td>
<td>64.4 ± 8.4</td>
<td>7 (88%)</td>
<td>7.2 ± 1.0</td>
<td>rTMS</td>
<td>Left prefrontal cortex</td>
<td>10 Hz, 110%, MEPs</td>
<td>N/A, 1 session</td>
<td>None</td>
<td>Significant pain reduction immediately after the treatment maintained 8 days after treatment start. No reduction in psychosocial scores</td>
</tr>
</tbody>
</table>

Notes: a)Data not available for the face subgroup. b)Pain intensity obtained through visual estimation from graphs.
Abbreviations: BPI, brief pain inventory; iTBS, intermittent theta burst stimulation; M1, primary motor cortex; M2, secondary motor cortex; TMS, transcranial magnetic stimulation; MEPs, motor evoked potentials; N/A, not available; rTMS, repetitive transcranial magnetic stimulation; S1, primary somatosensory cortex; S2, secondary somatosensory cortex.
The stimulation of M1 with high frequencies (≥ 5 Hz) of rTMS has been determined to have a definite analgesic effect (level A of evidence) in neuropathic pain, and its use is recommended for treating pain disorders.8 Nevertheless, a question arises as to what area of M1 should be stimulated: a) the somatotopic representation of the face area or b) the somatotopic representation of hand area, which has been shown to decrease pain in other areas than the hand when used in “non-diffuse” neuropathic pain disorders.43,44 The results of the present review showed that while the stimulation of the hand area led to significant pain intensity reduction effects in the majority of the included studies, stimulation of the face area was associated with more inconsistent results in OLP (in three of the six studies, no improvement was reported; Table 2). Although speculative, authors28 have proposed three main arguments to explain this discrepancy in the results: a) the difficulty to determine the “hot spot” and resting motor threshold in the face muscles when compared to the hand; b) the higher connectivity pattern of M1 representation of the hand relative to the M1 representation of the face with brain structures related with endogenous pain modulation; and c) the reduction of power due to the presence of thicker layers of cerebral spinal fluid (CSF) in proximal regions of the M1 representation of the face.

This review also showed that stimulation over the LPFC produced significant decreases in pain intensity in disorders such as BMS or neuropathic pain.19,20 Interestingly, Bockenstedt et al showed that the induced analgesic effects were independent from mood scores in fibromyalgia patients.19 However, the pilot nature of this study warrants caution when interpreting these conjectural findings. Right S2/M2 has also been investigated in one study having positive results.37 The authors hypothesized that the effectiveness of tDCS is limited to areas with active somatotopic representation, and the failure to produce analgesia could be due to the large inter-individual variability of the somatotopic map of the face. Nevertheless, it is important to note that this hypothesis is still speculative, and further research is needed to confirm these findings.

### Table 3 tDCS methodology and main results

<table>
<thead>
<tr>
<th>Study</th>
<th>Sample size</th>
<th>Age, years (mean ± SD)</th>
<th>Female</th>
<th>Pain intensity (mean ± SD) (0–10)</th>
<th>Type</th>
<th>Target area</th>
<th>Intensity, no. sessions</th>
<th>Duration</th>
<th>Adverse effects</th>
<th>Main results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Donnell et al, 2015</td>
<td>12 active12 sham</td>
<td>34.8±13.7</td>
<td>12 (100%)</td>
<td>3.4±1.5</td>
<td>HD 2 × 2 anodal</td>
<td>2 anodes over M1 (face) / 2 cathodes ant. (FC3 + FCS)</td>
<td>2 mA, 5 sessions</td>
<td>20 min</td>
<td>Mild HA, tingling, sleepiness (both)</td>
<td>Significant improvement in pain and mouth opening, maintained 4 weeks after treatment.</td>
</tr>
<tr>
<td>Hagenacker et al, 2014</td>
<td>10</td>
<td>58.7±6.0</td>
<td>5 (50%)</td>
<td>6.7±1.3</td>
<td>4 × 4 anodal</td>
<td>Anode over M1, cathode: suborbital</td>
<td>1 mA, 14 sessions</td>
<td>20 min</td>
<td>Slight itching and tingling</td>
<td>Significant improvement in pain, not attack frequency. It worked in purely paroxysmal cases, but not in the ones having persistent pain.</td>
</tr>
<tr>
<td>Oliveira et al, 2015</td>
<td>16 active+PT</td>
<td>23.8±7.3</td>
<td>15 (94%)</td>
<td>5.5±1.4</td>
<td>Anodal + PT</td>
<td>Anode over M1, cathode: suborbital</td>
<td>2 mA, 5 sessions</td>
<td>20 min</td>
<td>None</td>
<td>Both groups significantly improved, although no difference was observed between groups.</td>
</tr>
</tbody>
</table>

Abbreviations: HA, headache; HD, high definition; M1, primary motor cortex; PT, physical therapy; tDCS, transcranial direct current stimulation.
analgesic effects may be due to the proximity of this area to anatomical areas that play important roles in pain perception, known as the “pain matrix”47 and the high degree of connections observed in S2 and other brain locations during painful stimulation.48 Therefore, LPFC and S2/M2 areas could be considered as alternative target areas to M1 for the investigation of rTMS in chronic OFP.

According to our results, it appears that more sessions and more pulses per session were associated with longer-lasting effects. The study of Umezaki et al.,38 which used the 3,000 pulses per session and the most number of sessions (10 sessions), showed most durable effects (60 days after beginning of treatment). The latter study also stimulated at the highest intensity (110% of resting motor thresholds) with very few adverse effects. Two independent studies by Khedr et al.33 and Fricova et al.31 showed analgesic effects that outlasted 14 days with five rTMS sessions, suggesting that more sessions and pulses delivered are associated with more durable analgesic effects. All the included studies used rTMS protocols but one, which used iTBS.34 This technique is an adaptation of high frequency rTMS,11 and a protocol with bursts of 3–5 pulses at 50 Hz in intraburst and 5 Hz in interburst was used to excite neurons. However, evidence with regard to its possible use in OFP is very limited, as only one study used this protocol in OFP, showing modest and transient effects.34

In regard to its safety, rTMS seems to be a safe technique as only minor and transient adverse effects were reported in a minority of included studies. In fact, only two studies reported mild headaches, and five reported no incidence of any adverse effect. It is also important to mention that data related to safety were not available in four of the included studies.

tDCS

Regarding the use of tDCS in OFP treatment, data were more limited with only three studies being included in our review, which limits the interpretation of the results. Two of them assessed its use in TMD patients, while the other explored it in TN. As in rTMS, the stimulation protocols were not standardized across studies, although less methodological differences have usually been observed relative to rTMS studies in chronic pain.15 Although some studies stimulated areas like LFPC or primary visual cortex (V1) in the case of migraines, the M1 region seems the most common target for chronic pain treatment using anodal stimulation.15 This was also the case in the present systematic review, where all the included studies targeted M1. It has been determined that anodal stimulation of the left M1 (commonly used for more diffuse pains) has a probable effect on pain reduction in fibromyalgia (level B of evidence), but its use in neuropathic pain (level C in spinal cord lesion, and no recommendation in peripheral) is more debated.15 Interestingly, in TN patients, tDCS reduced pain intensity in the purely paroxysmal subgroup and not in TN patients with a concomitant diffuse background pain.40 The parameters and methodologies for stimulation were in line with the literature corresponding to spinally mediated neuropathic pain and fibromyalgia. Adverse effects were also minimal and only reported in two of the studies. These included mild headaches, tingling, and sleepiness, which were also reported in placebo groups.
As presented in this review, there is less tDCS data available when compared to rTMS to assess its use in OFP or other pain conditions. More evidence supports the use of rTMS for treating chronic pain, but some elements need to be considered. It has been speculated that rTMS may be more effective managing pain with neuropathic characteristics located in the upper limbs and face, while tDCS appears to be more effective treating musculoskeletal pain conditions such as fibromyalgia and in a minor way neuropathic pain located in the lower limb due to spinal cord lesion. This observation may be the reason why included rTMS studies were performed mostly in OFP disorders with neuropathic characteristics, while TMDs were only studied with tDCS.

Risk of bias and quality of the studies

According to our assessment, there was a considerable risk of bias present in all the included studies across different categories (Table 4), thus making the overall quality of the including studies fair (k=2) or poor in its vast majority (k=12). The lack of description and clarity of the randomization process, the absence of a concealment method or its omission in the report, and the non-blinding in the assessment of outcomes were some of the issues that increased the risk of bias. It also needs to be mentioned that we decided to assess the intake of anticonvulsants or GABAergic medications as another possible bias in the category of other risk of bias. The use of stable medication was allowed in the majority of the studies. Some of the medications to manage chronic OFP disorders, especially the ones with neuropathic characteristics, include anticonvulsants (sodium and calcium channel blockers) and GABA agonists among others. Although the interruption of these medications when stable can suppose an ethical concern and may increase the risk of TMS-induced seizures, it has been suggested that these medications can alter treatment outcomes and add noise to the therapeutic effects of rTMS and anodal tDCS, possibly compromising its optimal efficacy. Even though Ayache et al controlled for the possible influence of medications in active/sham stimulations in their analyses, only one study excluded participants taking this type of medications. However, the latter was a pilot study where only four participants (three of them with facial pain) were included. Therefore, despite not being clinically representative, investigating the effects of rTMS and tDCS in the absence of these medications may lead to different results. Another interesting route with more clinical meaning would be to investigate the effects of these neurostimulation techniques in the possible reduction of pain medication intake or drug sparing. Different studies have shown positive effects of both techniques in reducing opioid consumption in patients with substance abuse disorders or postsurgical pain. As the medications used to treat chronic pain are frequently associated with multiple side effects, drug interactions, and safety issues, the use of non-invasive stimulation to reduce its intake surface as appealing. Quantifying the medication intake with scales such as Medication Quantification Scale (MQS) before and after these interventions can be considered as an interesting outcome to explore. In addition, despite grey literature was searched in order to reduce it, the possible risk of publication bias also needs to be mentioned. In conclusion and in line with recent literature, our risk of bias assessment reinforces the need of improving the quality of rTMS and tDCS studies by reducing the possible sources of bias mentioned above.

Considerable heterogeneity was observed across studies. First, as this review aimed to be as inclusive as possible with regard to OFP disorders, disorders with different pathophysiological mechanisms and etiologies were studied, so the comparison between the results of these studies was somewhat difficult. In addition: a) some of the studies used a “flexible” inclusion criteria that included per se disorders with different pain characteristics; b) others did not report a specific diagnosis; and c) others were not specifically focused on OFP but in pain conditions that could present in the face (ie, neuropathic pain), making data extraction and interpretation quite complex. Second, outcomes also varied considerably between studies. Pain intensity was reported in different manners, including means or individual data of visual analog scale (VAS) or numerical rating scale (NRS), or different formulas calculating percentages of reduction (including or not sham reduction). And third, the report and application of rTMS sham protocols, which are important to assess pain improvement in a controlled design, also varied considerably among the included studies. These limitations and the low number of tDCS studies prevented us from considering the possibility of performing a meta-analysis, leading us to present the data in a more narrative manner.

Limitations

This systematic review has some limitations. As explained before, the quality of the included studies is not ideal, and inclusion of different OFP disorders makes our results less specific and broader. In addition, the exclusion of headache disorders affecting the orofacial region such as migraine or trigeminal autonomic cephalalgias (TACs) may be considered a limitation. However, considering that a) the inclusion of headaches in OFP disorders classifications still remains
Non-invasive brain stimulation in chronic OFP

controversial,44 b) systematic reviews and meta-analysis have already been performed in TMS/tDCS and migraine,22,65 and c) TACs are very rare disorders,66 we decided not to include headache disorders in our review. Finally, it is also important to mention that we did not assess in detail the quality and difference of applied sham protocols or the type of coil that was used.

Conclusion
This review assessed the use of non-invasive brain stimulation (TMS and tDCS) in chronic OFP disorders. Although TMS appears to be a safe and promising alternative to reduce pain intensity in different chronic OFP disorders, evidence is still quite limited, especially with regard to tDCS. Additional research effort is needed to characterize optimal brain stimulation parameters in order to promote TMS/tDCS immediate and long-term efficacy for treatment of chronic OFP disorders. Standardization of reported outcomes, homogeneity of samples, and reduction of bias are necessary to improve the quality of the studies and promote a better analysis of their results.

Acknowledgments
The authors would like to acknowledge Natalie Clairoux from Université de Montréal for her guidance and Estephane J. Moana Filho, DDS, MS, PhD, from University of Minnesota for his contributions.

Disclosure
The authors report no conflicts of interest in this work.

References


